Inhibrx Biosciences, Inc.
INBX
$82.96
$0.710.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -35.26M | -28.65M | -43.31M | -47.87M | -43.86M |
| Total Depreciation and Amortization | 583.00K | 661.00K | 675.00K | 689.00K | 760.00K |
| Total Amortization of Deferred Charges | 638.00K | 626.00K | 533.00K | 0.00 | 0.00 |
| Total Other Non-Cash Items | 3.63M | 3.21M | 2.88M | 3.45M | 3.46M |
| Change in Net Operating Assets | -3.42M | -5.80M | 3.32M | 4.00K | 9.36M |
| Cash from Operations | -33.82M | -29.95M | -35.90M | -43.72M | -30.28M |
| Capital Expenditure | -10.00K | 0.00 | -21.00K | -16.00K | -247.00K |
| Sale of Property, Plant, and Equipment | 3.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -7.00K | 0.00 | -21.00K | -16.00K | -247.00K |
| Total Debt Issued | 0.00 | 0.00 | 99.97M | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 352.00K | -- | -- | 0.00 | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -125.00K | -- | -- |
| Cash from Financing | 352.00K | 0.00 | 99.84M | 0.00 | 0.00 |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -33.48M | -29.95M | 63.92M | -43.74M | -30.53M |